A guidance raise is only as good as who controls the trigger
Q3 guidance moves look alike on a headline but differ in what they say about control. The companies that own their drivers have earned more trust than those waiting on a partner's calendar.
Same word, different promise
Read this quarter's headlines quickly and you would think the industry is in a raising mood. Eton lifted 2026 revenue guidance to more than $175 million from more than $145 million, and its Adjusted EBITDA target to more than 40% from more than 35%. Novavax raised full-year Non-GAAP Adjusted Total Revenue by $145 million, to $400 million at the mid-point. Ionis, by contrast, lowered 2026 product sales guidance for Tryngolza. It still reaffirmed total revenue, operating loss and cash guidance.
My argument is that the direction of a guidance change matters less than who holds the trigger. Guidance built on a company's own commercial execution is a different kind of statement from guidance that depends on someone else's decision. Leaders and boards should price the two differently.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Adjusted EBITDA is the headline number. This earnings season shows why the bridge matters more
Harrow, Liquidia and CorMedix each reported strong operating metrics beside very different GAAP and guidance pictures. Leaders should judge the bridge between those numbers, not the number on top.
The real divide this earnings season is runway: who sets the timeline, and who is set by it
Revenue growth, settlements and trial milestones all matter, but the Q3 filings show the balance sheet decides who can act on them at a time of their own choosing.
Litigation is a launch cost, and earnings season is finally pricing it that way
Liquidia's $389.7 million settlement charge and Harrow's guidance reset show that the cost of defending a franchise belongs in the business case, not in a footnote below adjusted EBITDA.